On November 21, Oklo Inc. fell 5.54% in Regular Trading, trading at $19.71 per share, with turnover of $238 million.
The move came after Guggenheim upgraded Oklo Inc. to Buy from Neutral and set a $38 price target, yet the stock still weakened, indicating that the market remains divided over valuation recovery and execution visibility after the prior sharp pullback.
Recent company updates have been constructive: third-quarter revenue was $1.9 million, above expectations, while cash, equivalents, and marketable securities stood at about $3.13 billion. Oklo Inc. also disclosed multiyear HALEU supply agreements with Centrus, including $35 million of prepayments and planned deliveries from 2029 to 2031, and said the DOE cleared Groves-1 for unrestricted research, testing, and training operations. Even so, the latest trading suggests positive catalysts have not yet produced a unified risk-on response.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments